Detalles de la búsqueda
1.
Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.
Methods
; 154: 10-20, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30326272
2.
Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.
Immunol Rev
; 270(1): 132-51, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26864109
3.
Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.
J Immunol
; 195(7): 3198-205, 2015 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26320252
4.
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
Blood
; 124(20): 3165-71, 2014 Nov 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-25274508
5.
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
J Thromb Haemost
; 22(2): 430-440, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37940048
6.
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer.
Cancer Immunol Res
; 2024 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558120
7.
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Cancer Immunol Res
; : OF1-OF12, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38563577
8.
Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement.
Antibodies (Basel)
; 12(2)2023 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37218902
9.
Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A.
MAbs
; 15(1): 2222441, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37339067
10.
Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease.
Nat Commun
; 14(1): 8502, 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38135691
11.
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering.
MAbs
; 14(1): 2068213, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35482905
12.
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants.
MAbs
; 14(1): 2040350, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35293276
13.
Novel myostatin-specific antibody enhances muscle strength in muscle disease models.
Sci Rep
; 11(1): 2160, 2021 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33495503
14.
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.
Cancer Discov
; 11(1): 158-175, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32847940
15.
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
Anticancer Drugs
; 21(10): 907-16, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20847643
16.
Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment.
Cell Rep
; 33(12): 108542, 2020 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33357423
17.
Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering.
Drug Metab Pharmacokinet
; 34(1): 25-41, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30472066
18.
Humanization and Simultaneous Optimization of Monoclonal Antibody.
Methods Mol Biol
; 1904: 213-230, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30539472
19.
Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency.
MAbs
; 11(4): 632-638, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30898021
20.
Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.
Clin Cancer Res
; 13(9): 2745-50, 2007 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17473208